Clinical trials: Advanced Solid Tumors (Phase 1)
Advanced Solid Tumor Malignancies
JSKN016HC in Patients With Advanced or Metastatic Solid Malignant Tumors
This is a Phase I, open-label, multicenter, first-in-human study to evaluate the safety, tolerability, PK/pharmacodynamic (PD) characteristics, and anti-tumor activity of JSKN016HC in subjects with advanced malignant solid tumors.
- Trial name
- NCT07475559
- Testing
- JSKN016HC
- Where
- Australia
- Volunteers
- 42 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Solid Tumors
Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement
The purpose of the study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ALN-VSP02, an RNAi therapeutic, in patients with advanced solid tumors with liver involvement.
- Trial name
- NCT00882180
- Testing
- ALN-VSP02
- Where
- 10 sites in United States, Spain
- Volunteers
- 41 people
- Sponsor
- Alnylam Pharmaceuticals
Neoplasms
Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors
The purpose of this Phase I study is to test the safety of rhuMAb 2C4 to see what effects (good and bad) it has on patients with certain types of cancer, and also to find the highest dose of rhuMAb that can be given without…
- Trial name
- NCT00027027
- Testing
- rhuMAb 2C4
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Genentech, Inc.
Advanced Solid Tumors
A Phase I Study of MSB2311 in Advanced Solid Tumors
This is a phase I study to determine the safety and toxicity, PK/PD, immunogenicity, biomarkers, anti-tumor activity and establish a preliminary recommended Phase 2 dose (RP2D) in subjects with advanced solid tumors.
- Trial name
- NCT03463473
- Testing
- 3 mg/kg Q3W MSB2311 Injection, 10 mg/kg Q3W MSB2311 Injection, 20 mg/kg Q3W MSB2311 Injection
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Advanced Solid Tumors
A First-in-human Study of GENA-104A16 in Patients With Advanced Solid Tumors
This is a first in human phase I , open label study to evaluate the safety and tolerability of GENA 104A16 administered as a single agent by intravenous (IV) once every 2 weeks ( q2w (1 cycle = 2 weeks) in patients with advanced…
- Trial name
- NCT06235541
- Testing
- GENA-104A16
- Where
- South Korea
- Sponsor
- Genome & Company
Malignant Neoplasm
A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Patients With Advanced Cancer
NBM-BMX is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by NatureWise. NBM-BMX is a histone deacetylase (HDAC) inhibitor and has been shown to be particularly active against HDAC8.
- Trial name
- NCT03726294
- Testing
- NBM-BMX softgel capsules
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- NatureWise Biotech & Medicals Corporation
Solid Tumors, Advanced Solid Tumors
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.
- Conditions
- Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
- Trial name
- NCT05836324
- Testing
- INCA33890, bevacizumab, FOLFIRI
- Where
- 39 sites in United States, China and 7 more
- Volunteers
- 570 people
- Sponsor
- Incyte Corporation
Solid Tumor, Melanoma
A Study of TRK-950 in Patients With Advanced Solid Tumors
Part 1 To determine the safety and tolerability of TRK-950 in patients with advanced solid tumors Part 2 To determine the safety and tolerability of TRK-950 in combination with nivolumab(NIVO) in patients with advanced solid…
- Trial name
- NCT05423262
- Testing
- TRK-950, Nivolumab
- Where
- 10 sites in Japan
- Volunteers
- 49 people
- Sponsor
- Toray Industries, Inc
Advanced Solid Tumor
A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)
The Purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of hSTC810 monotherapy in participants with advanced solid tumors.
- Trial name
- NCT05231746
- Testing
- hSTC810
- Where
- 5 sites in United States, South Korea
- Volunteers
- 47 people
- Sponsor
- STCube, Inc.
Advanced Solid Tumors
Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors
Single arm, open label, Phase I, dose-escalation study of indibulin in combination with erlotinib in subjects with advanced histologically confirmed, solid tumors for which no standard therapy exists and for whom treatment with…
- Trial name
- NCT00591383
- Testing
- indibulin, erlotinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Alaunos Therapeutics
Advanced Solid Tumor, Gastric Cancer
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-ADC in patients with advanced cancer
- Conditions
- Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT05156866
- Testing
- TORL-2-307-ADC
- Where
- 12 sites in United States, South Korea
- Volunteers
- 163 people
- Sponsor
- TORL Biotherapeutics, LLC
Advanced Solid Tumors
A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of Niraparib in Japanese participants with advanced solid tumors.
- Trial name
- NCT03497429
- Testing
- Niraparib
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Takeda
Solid Tumors
Anti-EGFR Immunoliposomes in Solid Tumors
Background: Site-specific delivery of anti-cancer therapeutics is paramount for both reducing nonspecific toxicities and increasing efficacy of chemotherapeutic agents.
- Trial name
- NCT01702129
- Testing
- anti-EGFR immunoliposomes loaded with doxorubicin
- Where
- Switzerland
- Volunteers
- 26 people
- Sponsor
- University Hospital, Basel, Switzerland
Cancer, Malignant Tumors
A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD) of E7974 after bolus IV administration, on Day 1 of a 21-day cycle, to patients with advanced solid tumors that have progressed following effective…
- Trial name
- NCT00165802
- Testing
- E7974
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Eisai Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Oxaliplatin and Gemcitabine in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004220
- Testing
- gemcitabine hydrochloride, oxaliplatin
- Where
- 3 sites in United States
- Sponsor
- City of Hope Medical Center
Breast Cancer, Biliary Tract Carcinoma
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
- Conditions
- Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer
- Trial name
- NCT05123482
- Testing
- AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib)
- Where
- 67 sites in United States, Australia and 13 more
- Volunteers
- 460 people
- Sponsor
- AstraZeneca
Tumors
Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors
This is a Phase I, open-label, dose-escalation study on subjects with advanced solid tumors. This is the first study of hCBE-11 in humans and is designed to determine the safety and how well patients tolerate this investigational…
- Trial name
- NCT00105170
- Testing
- hCBE-11
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Biogen
Cancer, Tumor, Solid
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502…
- Conditions
- Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer
- Trial name
- NCT06090266
- Testing
- OR502, Cemiplimab
- Where
- 4 sites in United States
- Volunteers
- 168 people
- Sponsor
- OncoResponse, Inc.
Advanced Solid Cancer, Advanced Solid Tumor (Phase 1)
A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
This is a Phase 1, open-label, dose-escalation study to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of APX-343A monotherapy (Part A) and in combination with pembrolizumab (Part B) in subjects…
- Trial name
- NCT07123415
- Testing
- APX-343A, Pembrolizumab
- Where
- 3 sites in South Korea
- Volunteers
- 110 people
- Sponsor
- Aptabio Therapeutics, Inc.
Solid Tumor
Autologous Tumour Vaccine Trial
Phase 1 trial to evaluate the feasibility of preparation, safety, tolerability and response to a personalised autologous tumour vaccine (ATV) formulated with Advax adjuvant when administered to patients with advanced solid…
- Trial name
- NCT05807035
- Testing
- Radvax
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Vaxine Pty Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.